drugset
drugset / Trial / NCT02225093

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

NCT02225093 ↗

Phase 1 Completed 12 enrolled Astellas Pharma Europe B.V. Medivation, Inc. · collab
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study evaluates how once daily enzalutamide affects the metabolism of caffeine and dextromethorphan in men with prostate cancer by measuring concentrations of these drugs and their metabolites in plasma.

Timeline

Start
2013-10-02
Primary completion
2014-02-03
Completion
2014-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Caffeine Small molecule — Oral
Subject Dextromethorphan Unknown — Oral
Subject Enzalutamide Other / unclassified — Oral

Indications

prostate cancer